RTP Mobile Logo

Thursday, January 17, 2019, San Francisco, California — 6:45 PM – 8:30 PM

Cases from the Community: Clinical Investigators Provide Perspectives on Actual Patients with Pancreatic Cancer

Event Details

San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

6:30 PM – 6:45 PM — Registration
6:45 PM – 8:30 PM — Educational Dinner Meeting

Meeting Room:
Yerba Buena Ballroom, Salon 9-15 (Lower B2 Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Andrew E Hendifar, MD
Medical Director, Pancreatic Cancer
Gastrointestinal and Neuroendocrine Malignancies
Cedars-Sinai Medical Center
Los Angeles, California

Eileen M O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head
Hepatopancreaticobiliary/Neuroendocrine Cancers Gastrointestinal Oncology Service
Associate Director

David M Rubenstein Center for
Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Philip A Philip, MD, PhD
Kathryn Cramer Endowed Chair in Cancer Research
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Margaret A Tempero, MD
Director, UCSF Pancreas Center
The Rombauer Family Distinguished
Professorship in Pancreas Cancer Clinical
and Translational Science
Leader, Pancreas Cancer Program
Professor of Medicine, Division of Hematology and Oncology
University of California, San Francisco
San Francisco, California

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2019 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2019 Gastrointestinal Cancers Symposium.


MODULE 1: Available and Emerging Research Guiding the Treatment of Resectable or Borderline Resectable Pancreatic Adenocarcinoma (PAD) — Dr Tempero

Topics to be Addressed During Case Discussion and Faculty Presentation

  • Eligibility for and key efficacy and safety outcomes from the Phase III Unicancer GI PRODIGE 24/CCTG PA.6 trial of adjuvant mFOLFIRINOX versus gemcitabine for patients with resected PAD
  • Clinical implications of the GI PRODIGE 24 study and patient selection for adjuvant mFOLFIRINOX
  • Design of, entry criteria for and primary and secondary endpoints being assessed in the Phase III APACT trial evaluating nanoparticle albumin-bound (nab) paclitaxel/gemcitabine in the adjuvant setting
  • Improvements in overall survival, recurrence rates and rates of resection observed with the use of preoperative chemoradiation therapy compared to immediate surgery in patients with resectable and borderline resectable PAD enrolled in the Phase III PREOPANC-1 trial; clinical implications
  • Available data with and clinical use of contemporary chemotherapy regimens (eg, mFOLFIRINOX, nab paclitaxel/gemcitabine) with or without radiation therapy as neoadjuvant treatment for resectable or borderline resectable disease

MODULE 2: Patient- and Disease-Specific Factors Informing the Selection of Therapy for Locally Advanced, Unresectable PAD (LAPC); Selection of First-Line Treatment for Metastatic Disease — Dr Philip

Topics to be Addressed During Case Discussion and Faculty Presentation

  • Multidisciplinary considerations in the management of LAPC that has not metastasized to other organs; use of radiation therapy alone versus chemoradiation therapy versus chemotherapy alone
  • Available data with and ongoing evaluation of nab paclitaxel/gemcitabine or FOLFIRINOX in patients with LAPC
  • Impact of earlier use of contemporary chemotherapy regimens (eg, neoadjuvant/adjuvant mFOLFIRINOX and nab paclitaxel/gemcitabine) on therapeutic selection in the metastatic setting
  • Clinical factors influencing the choice of first-line treatment for metastatic disease (eg, age, performance status, prior therapeutic exposure, comorbidities)
  • Ongoing evaluation of nanoparticle liposomal irinotecan (nal-IRI) as a component of first-line therapy

MODULE 3: Optimal Management of Metastatic Disease After Progression on First-Line Therapy — Dr O’Reilly

Topics to be Addressed During Case Discussion and Faculty Presentation

  • Recent meta-analysis of second-line clinical trials in progressive PAD; improvement in overall and progression-free survival associated with the use of irinotecan-based regimens compared to oxaliplatin-based therapy and clinical implications
  • Published research experience with, patient selection for and practical integration of nal-IRI in relapsed metastatic PAD
  • Side effects and toxicities associated with nal-IRI and indications for dose delays, reductions and discontinuations
  • Other evidence-based chemotherapeutic agents or regimens for patients who have experienced disease progression on multiple lines of systemic therapy and can receive additional treatment

MODULE 4: Novel Agents and Strategies Under Investigation — Dr Hendifar

Topics to be Addressed During Case Discussion and Faculty Presentation

  • Incidence of BRCA1/2 and PALB2 mutations in patients with PAD, benefits and limitations of available genetic testing platforms and impact on prognosis and current clinical management
  • Early clinical experience with and ongoing Phase III evaluation of PARP inhibitors in patients with PAD and a documented BRCA mutation
  • Biologic rationale for targeting hyaluronan (HA) in PAD; early safety and efficacy of PEGPH20 in patients with previously untreated PAD and high HA levels and ongoing Phase III evaluation (HALO-301)
  • Early activity and safety with the use of the stemness inhibitor napabucasin in combination with nab paclitaxel/gemcitabine for metastatic PAD
  • Other novel agents and strategies under active investigation

CE Information

Target Audience:
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of pancreatic cancer.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Develop an evidence-based strategy for the treatment of resectable or borderline resectable pancreatic adenocarcinoma (PAD), exploring the role of neoadjuvant and adjuvant chemotherapy and/or radiation therapy.
  • Appraise available and emerging clinical trial data documenting the utility of contemporary combination chemotherapy regimens (eg, FOLFIRINOX, nab paclitaxel/gemcitabine) in the neoadjuvant and adjuvant settings, and determine what role, if any, these strategies should play in the current care of patients diagnosed with resectable PAD.
  • Consider age, performance status, prior therapeutic exposure and other clinical and logistical factors in the selection and sequencing of systemic therapy for patients with locally advanced or metastatic PAD.
  • Appreciate the efficacy and tolerability profile of nanoliposomal irinotecan (nal-IRI) for treatment-refractory metastatic PAD, and optimally incorporate this agent into patient-care algorithms.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of approved systemic regimens for the management of locally advanced or metastatic PAD to support quality of life and continuation of therapy.
  • Describe the rationale for testing patients with metastatic PAD for mutations in homology-directed DNA repair predisposition genes (eg, BRCA1, BRCA2 and PALB2), and advise individuals found to harbor these genetic abnormalities about participation in clinical trials evaluating PARP inhibition.
  • Recall the biologic rationale for and available and emerging data with other investigational agents currently in clinical testing for PAD, and, where applicable, refer eligible patients for trial participation or other expanded access programs.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from Celgene Corporation, Halozyme Inc and Ipsen Biopharmaceuticals Inc.


San Francisco Marriott Marquis
780 Mission Street
San Francisco, CA 94103
Hotel Phone: (415) 896-1600

Meeting Room:
Yerba Buena Ballroom, Salon 9-15 (Lower B2 Level)

The San Francisco Marriott Marquis is located just 2 blocks (less than 0.2 miles) from the Moscone Convention Center where the 2019 Gastrointestinal Cancers Symposium is taking place.



Thank you for your interest in our CME program. At this time online preregistration is closed for this event. Onsite registration will be open starting at 6:30 PM on Thursday, January 17th. If you are interested in attending, please visit our registration desk located outside the Yerba Buena Ballroom, Salon 9-15, on the B2 Level of the San Francisco Marriott Marquis hotel (780 Mission Street, San Francisco, CA 94103).

If seats become available for the program, we will accept new registrations with priority given to clinicians in practice on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.


Registration for this event is independent of registration for the Gastrointestinal Cancers Symposium.